;PMID: 9112700
;source_file_632.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..109] = [t:48..109]
;2)section:[e:113..146] = [t:113..146]
;3)section:[e:150..246] = [t:150..246]
;4)sentence:[e:250..407] = [t:250..407]
;5)sentence:[e:409..519] = [t:409..519]
;6)sentence:[e:520..723] = [t:520..723]
;7)sentence:[e:725..872] = [t:725..872]
;8)sentence:[e:874..1067] = [t:874..1067]
;9)sentence:[e:1068..1159] = [t:1068..1159]
;10)sentence:[e:1160..1277] = [t:1160..1277]
;11)sentence:[e:1278..1489] = [t:1278..1489]
;12)sentence:[e:1490..1650] = [t:1490..1650]
;13)sentence:[e:1651..1921] = [t:1651..1921]
;14)section:[e:1925..1969] = [t:1925..1969]

;section 0 Span:0..42
;Pol J Pharmacol. 1996 Nov-Dec;48(6):601-8.
(SEC
  (FRAG (NNP:[0..3] Pol) (NNP:[4..5] J) (NNP:[6..15] Pharmacol) (.:[15..16] .)
        (``:[17..21] 1996) (DT:[22..24] No) (JJ:[24..31] v-Dec;4)
        (CD:[31..32] 8) (NN:[32..33] -LRB-) (NN:[33..34] 6) (NN:[34..35] -RRB-)
        (::[35..36] :) (CD:[36..38] 60) (CD:[38..41] 1-8) (.:[41..42] .)))

;sentence 1 Span:48..109
;Effect of carbamazepine on the pharmacokinetics of promazine.
;[58..71]:substance:"carbamazepine"
;[99..108]:substance:"promazine"
(SENT
  (NP-HLN
    (NP (NN:[48..54] Effect))
    (PP (IN:[55..57] of)
      (NP (NN:[58..71] carbamazepine)))
    (PP (IN:[72..74] on)
      (NP
        (NP (DT:[75..78] the) (NNS:[79..95] pharmacokinetics))
        (PP (IN:[96..98] of)
          (NP (NN:[99..108] promazine)))))
    (.:[108..109] .)))

;section 2 Span:113..146
;Syrek M, Wojcikowski J, Daniel W.
(SEC
  (FRAG (NNP:[113..118] Syrek) (NNP:[119..121] M,) (NNP:[122..133] Wojcikowski)
        (NNP:[134..136] J,) (NNP:[137..143] Daniel) (NNP:[144..146] W.)))

;section 3 Span:150..246
;Department of Pharmacokinetics and Drug Metabolism, Polish Academy of
;Sciences,  Krakow, Poland.
(SEC
  (FRAG (NNP:[150..160] Department) (IN:[161..163] of)
        (NNP:[164..180] Pharmacokinetics) (CC:[181..184] and)
        (NNP:[185..189] Drug) (NNP:[190..200] Metabolism) (,:[200..201] ,)
        (NNP:[202..208] Polish) (NNP:[209..216] Academy) (IN:[217..219] of)
        (NNPS:[220..228] Sciences) (,:[228..229] ,) (NNP:[231..237] Krakow)
        (,:[237..238] ,) (NNP:[239..245] Poland) (.:[245..246] .)))

;sentence 4 Span:250..407
;Combinations of neuroleptics and carbamazepine are administered to
;psychiatric  patients in the therapy of mania, manic-depressive illness and
;schizophrenia.
;[266..278]:substance:"neuroleptics"
;[283..296]:substance:"carbamazepine"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[250..262] Combinations))
      (PP (IN:[263..265] of)
        (NP (NNS:[266..278] neuroleptics) (CC:[279..282] and)
            (NN:[283..296] carbamazepine))))
    (VP (VBP:[297..300] are)
      (VP (VBN:[301..313] administered)
        (NP-1 (-NONE-:[313..313] *))
        (PP-CLR (TO:[314..316] to)
          (NP (JJ:[317..328] psychiatric) (NNS:[330..338] patients)))
        (PP (IN:[339..341] in)
          (NP
            (NP (DT:[342..345] the) (NN:[346..353] therapy))
            (PP (IN:[354..356] of)
              (NP
                (NP (NN:[357..362] mania))
                (,:[362..363] ,)
                (NP
                  (ADJP (JJ:[364..369] manic) (HYPH:[369..370] -)
                        (JJ:[370..380] depressive))
                  (NN:[381..388] illness))
                (CC:[389..392] and)
                (NP (NN:[393..406] schizophrenia))))))))
    (.:[406..407] .)))

;sentence 5 Span:409..519
;The present study was aimed at assessing the influence of carbamazepine on
;the  pharmacokinetics of promazine.
;[467..480]:substance:"carbamazepine"
;[509..518]:substance:"promazine"
(SENT
  (S
    (NP-SBJ-1 (DT:[409..412] The) (JJ:[413..420] present) (NN:[421..426] study))
    (VP (VBD:[427..430] was)
      (VP (VBN:[431..436] aimed)
        (NP-1 (-NONE-:[436..436] *))
        (PP-CLR (IN:[437..439] at)
          (S-NOM
            (NP-SBJ (-NONE-:[439..439] *))
            (VP (VBG:[440..449] assessing)
              (NP
                (NP (DT:[450..453] the) (NN:[454..463] influence))
                (PP (IN:[464..466] of)
                  (NP (NN:[467..480] carbamazepine)))
                (PP (IN:[481..483] on)
                  (NP
                    (NP (DT:[484..487] the) (NNS:[489..505] pharmacokinetics))
                    (PP (IN:[506..508] of)
                      (NP (NN:[509..518] promazine)))))))))))
    (.:[518..519] .)))

;sentence 6 Span:520..723
;Male Wistar rats received promazine and/or  carbamazepine twice daily for two
;weeks (promazine, 10 mg/kg ip; carbamazepine,  15 mg/kg ip during the 1st,
;and 20 mg/kg ip during the 2nd week of treatment).
;[546..555]:substance:"promazine"
;[564..577]:substance:"carbamazepine"
;[578..583]:quantitative-value:"twice"
;[584..589]:quantitative-units:"daily"
;[594..597]:quantitative-value:"two"
;[598..603]:quantitative-units:"weeks"
;[605..614]:substance:"promazine"
;[616..618]:quantitative-value:"10"
;[619..624]:quantitative-units:"mg/kg"
;[629..642]:substance:"carbamazepine"
;[645..647]:quantitative-value:"15"
;[648..653]:quantitative-units:"mg/kg"
;[668..671]:quantitative-value:"1st"
;[677..679]:quantitative-value:"20"
;[680..685]:quantitative-units:"mg/kg"
;[700..703]:quantitative-value:"2nd"
;[704..708]:quantitative-units:"week"
(SENT
  (S
    (NP-SBJ (JJ:[520..524] Male) (NNP:[525..531] Wistar) (NNS:[532..536] rats))
    (VP (VBD:[537..545] received)
      (NP (NN:[546..555] promazine) (CC:[556..562] and/or)
          (NN:[564..577] carbamazepine))
      (ADVP
        (ADVP (RB:[578..583] twice))
        (RB:[584..589] daily))
      (PP-TMP (IN:[590..593] for)
        (NP (CD:[594..597] two) (NNS:[598..603] weeks)))
      (PRN (-LRB-:[604..605] -LRB-)
        (FRAG
          (NP (NN:[605..614] promazine))
          (,:[614..615] ,)
          (NP (CD:[616..618] 10) (NN:[619..621] mg))
          (PP (SYM:[621..622] /)
            (NP (NN:[622..624] kg) (NN:[625..627] ip))))
        (::[627..628] ;)
        (FRAG
          (NP (NN:[629..642] carbamazepine))
          (,:[642..643] ,)
          (NP
            (NP
              (NP
                (NP (CD:[645..647] 15) (NN:[648..650] mg))
                (PP (SYM:[650..651] /)
                  (NP (NN:[651..653] kg) (NN:[654..656] ip))))
              (PP-TMP (IN:[657..663] during)
                (NP
                  (NP (DT:[664..667] the) (JJ:[668..671] 1st)
                    (NML-1 (-NONE-:[671..671] *RNR*)))
                  (PP-2 (-NONE-:[671..671] *RNR*)))))
            (,:[671..672] ,) (CC:[673..676] and)
            (NP
              (NP
                (NP (CD:[677..679] 20) (NN:[680..682] mg))
                (PP (SYM:[682..683] /)
                  (NP (NN:[683..685] kg) (NN:[686..688] ip))))
              (PP-TMP (IN:[689..695] during)
                (NP
                  (NP (DT:[696..699] the) (JJ:[700..703] 2nd)
                    (NML-1 (-NONE-:[703..703] *RNR*)))
                  (PP-2 (-NONE-:[703..703] *RNR*)))))
            (NML-1 (NN:[704..708] week))
            (PP-2 (IN:[709..711] of)
              (NP (NN:[712..721] treatment)))))
        (-RRB-:[721..722] -RRB-)))
    (.:[722..723] .)))

;sentence 7 Span:725..872
;In a short time (1 h) after administration, carbamazepine had a tendency to 
;increase the concentration of promazine in the blood plasma and brain.
;[742..743]:quantitative-value:"1"
;[744..745]:quantitative-units:"h"
;[769..782]:substance:"carbamazepine"
;[832..841]:substance:"promazine"
(SENT
  (S
    (PP (IN:[725..727] In)
      (NP
        (NP
          (NP (DT:[728..729] a) (JJ:[730..735] short) (NN:[736..740] time))
          (PRN (-LRB-:[741..742] -LRB-)
            (NP (CD:[742..743] 1) (NN:[744..745] h))
            (-RRB-:[745..746] -RRB-)))
        (PP (IN:[747..752] after)
          (NP (NN:[753..767] administration)))))
    (,:[767..768] ,)
    (NP-SBJ (NN:[769..782] carbamazepine))
    (VP (VBD:[783..786] had)
      (NP (DT:[787..788] a) (NN:[789..797] tendency)
        (S
          (NP-SBJ (-NONE-:[797..797] *))
          (VP (TO:[798..800] to)
            (VP (VB:[802..810] increase)
              (NP
                (NP (DT:[811..814] the) (NN:[815..828] concentration))
                (PP (IN:[829..831] of)
                  (NP (NN:[832..841] promazine))))
              (PP-LOC (IN:[842..844] in)
                (NP (DT:[845..848] the)
                  (NML
                    (NML (NN:[849..854] blood) (NN:[855..861] plasma))
                    (CC:[862..865] and)
                    (NML (NN:[866..871] brain))))))))))
    (.:[871..872] .)))

;sentence 8 Span:874..1067
;Lineweaver-Burk's analysis showed that carbamazepine added in vitro 
;competitively inhibited the N-demethylation of promazine in liver microsomes,
; without affecting the sulphoxidation process.
;[913..926]:substance:"carbamazepine"
;[990..999]:substance:"promazine"
(SENT
  (S
    (NP-SBJ
      (NP (NNP:[874..884] Lineweaver) (HYPH:[884..885] -) (NNP:[885..889] Burk)
          (POS:[889..891] 's))
      (NN:[892..900] analysis))
    (VP (VBD:[901..907] showed)
      (SBAR (IN:[908..912] that)
        (S
          (NP-SBJ
            (NP (NN:[913..926] carbamazepine))
            (VP (VBN:[927..932] added)
              (NP (-NONE-:[932..932] *))
              (ADVP (FW:[933..935] in) (FW:[936..941] vitro))))
          (ADVP (RB:[943..956] competitively))
          (VP (VBD:[957..966] inhibited)
            (NP
              (NP (DT:[967..970] the) (NN:[971..986] N-demethylation))
              (PP (IN:[987..989] of)
                (NP (NN:[990..999] promazine))))
            (PP-LOC (IN:[1000..1002] in)
              (NP (NN:[1003..1008] liver) (NNS:[1009..1019] microsomes)))
            (,:[1019..1020] ,)
            (PP (IN:[1022..1029] without)
              (S-NOM
                (NP-SBJ (-NONE-:[1029..1029] *))
                (VP (VBG:[1030..1039] affecting)
                  (NP (DT:[1040..1043] the) (NN:[1044..1058] sulphoxidation)
                      (NN:[1059..1066] process)))))))))
    (.:[1066..1067] .)))

;sentence 9 Span:1068..1159
;The effect was reflected in vivo  (1 h) by an increased
;promazine/desmethylpromazine ratio.
;[1103..1104]:quantitative-value:"1"
;[1105..1106]:quantitative-units:"h"
;[1124..1133]:substance:"promazine"
;[1134..1152]:substance:"desmethylpromazine"
(SENT
  (S
    (NP-SBJ-1 (DT:[1068..1071] The) (NN:[1072..1078] effect))
    (VP (VBD:[1079..1082] was)
      (VP (VBN:[1083..1092] reflected)
        (NP-1 (-NONE-:[1092..1092] *))
        (ADVP (FW:[1093..1095] in) (FW:[1096..1100] vivo))
        (PRN (-LRB-:[1102..1103] -LRB-)
          (NP (CD:[1103..1104] 1) (NN:[1105..1106] h))
          (-RRB-:[1106..1107] -RRB-))
        (PP-MNR (IN:[1108..1110] by)
          (NP (DT:[1111..1113] an) (VBN:[1114..1123] increased)
            (NML
              (NML (NN:[1124..1133] promazine))
              (PP (SYM:[1133..1134] /)
                (NP (NN:[1134..1152] desmethylpromazine))))
            (NN:[1153..1158] ratio)))))
    (.:[1158..1159] .)))

;sentence 10 Span:1160..1277
;After a long time  interval (6 h, 12 h), carbamazepine decreased the
;concentration of promazine and  its metabolites.
;[1189..1190]:quantitative-value:"6"
;[1191..1192]:quantitative-units:"h"
;[1194..1196]:quantitative-value:"12"
;[1197..1198]:quantitative-units:"h"
;[1201..1214]:substance:"carbamazepine"
;[1246..1255]:substance:"promazine"
;[1265..1276]:substance:"metabolites"
(SENT
  (S
    (PP (IN:[1160..1165] After)
      (NP
        (NP (DT:[1166..1167] a) (JJ:[1168..1172] long) (NN:[1173..1177] time)
            (NN:[1179..1187] interval))
        (PRN (-LRB-:[1188..1189] -LRB-)
          (NP
            (NP (CD:[1189..1190] 6) (NN:[1191..1192] h))
            (,:[1192..1193] ,)
            (NP (CD:[1194..1196] 12) (NN:[1197..1198] h)))
          (-RRB-:[1198..1199] -RRB-))))
    (,:[1199..1200] ,)
    (NP-SBJ (NN:[1201..1214] carbamazepine))
    (VP (VBD:[1215..1224] decreased)
      (NP
        (NP (DT:[1225..1228] the) (NN:[1229..1242] concentration))
        (PP (IN:[1243..1245] of)
          (NP
            (NP (NN:[1246..1255] promazine))
            (CC:[1256..1259] and)
            (NP (PRP$:[1261..1264] its) (NNS:[1265..1276] metabolites))))))
    (.:[1276..1277] .)))

;sentence 11 Span:1278..1489
;In vitro studies into the promazine metabolism, conducted on  microsomes from
;rats treated with promazine and/or carbamazepine, did not show  acceleration
;of its demethylation or sulphoxidation by carbamazepine.
;[1304..1313]:substance:"promazine"
;[1374..1383]:substance:"promazine"
;[1391..1404]:substance:"carbamazepine"
;[1475..1488]:substance:"carbamazepine"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP
          (ADJP (FW:[1278..1280] In) (FW:[1281..1286] vitro))
          (NNS:[1287..1294] studies))
        (PP (IN:[1295..1299] into)
          (NP (DT:[1300..1303] the) (NN:[1304..1313] promazine)
              (NN:[1314..1324] metabolism))))
      (,:[1324..1325] ,)
      (VP (VBN:[1326..1335] conducted)
        (NP (-NONE-:[1335..1335] *))
        (PP (IN:[1336..1338] on)
          (NP
            (NP (NNS:[1340..1350] microsomes))
            (PP (IN:[1351..1355] from)
              (NP
                (NP (NNS:[1356..1360] rats))
                (VP (VBN:[1361..1368] treated)
                  (NP (-NONE-:[1368..1368] *))
                  (PP-MNR (IN:[1369..1373] with)
                    (NP (NN:[1374..1383] promazine) (CC:[1384..1390] and/or)
                        (NN:[1391..1404] carbamazepine))))))))))
    (,:[1404..1405] ,)
    (VP (VBD:[1406..1409] did) (RB:[1410..1413] not)
      (VP (VB:[1414..1418] show)
        (NP
          (NP (NN:[1420..1432] acceleration))
          (PP (IN:[1433..1435] of)
            (NP
              (NP (PRP$:[1436..1439] its) (NN:[1440..1453] demethylation)
                  (CC:[1454..1456] or) (NN:[1457..1471] sulphoxidation))
              (PP (IN:[1472..1474] by)
                (NP (NN:[1475..1488] carbamazepine))))))))
    (.:[1488..1489] .)))

;sentence 12 Span:1490..1650
;The  obtained results suggest that induction of promazine metabolism by
;carbamazepine  involves metabolic pathways other than N-demethylation or
;sulphoxidation.
;[1538..1547]:substance:"promazine"
;[1562..1575]:substance:"carbamazepine"
(SENT
  (S
    (NP-SBJ (DT:[1490..1493] The) (VBN:[1495..1503] obtained)
            (NNS:[1504..1511] results))
    (VP (VBP:[1512..1519] suggest)
      (SBAR (IN:[1520..1524] that)
        (S
          (NP-SBJ
            (NP (NN:[1525..1534] induction))
            (PP (IN:[1535..1537] of)
              (NP (NN:[1538..1547] promazine) (NN:[1548..1558] metabolism)))
            (PP (IN:[1559..1561] by)
              (NP (NN:[1562..1575] carbamazepine))))
          (VP (VBZ:[1577..1585] involves)
            (NP
              (NP (JJ:[1586..1595] metabolic) (NNS:[1596..1604] pathways))
              (ADJP (JJ:[1605..1610] other)
                (PP (IN:[1611..1615] than)
                  (NP (NN:[1616..1631] N-demethylation) (CC:[1632..1634] or)
                      (NN:[1635..1649] sulphoxidation)))))))))
    (.:[1649..1650] .)))

;sentence 13 Span:1651..1921
;It has  been concluded that when a phenothiazine neuroleptic, such as
;promazine, is  administered jointly with carbamazepine, a slight increase in
;the neuroleptic  concentration may be expected in a short time after
;administration, followed by  its significant decrease.
;[1686..1711]:substance:"phenothiazine neuroleptic"
;[1721..1730]:substance:"promazine"
;[1762..1775]:substance:"carbamazepine"
;[1802..1813]:substance:"neuroleptic"
(SENT
  (S
    (NP-SBJ-3
      (NP (PRP:[1651..1653] It))
      (SBAR-4 (-NONE-:[1653..1653] *EXP*)))
    (VP (VBZ:[1654..1657] has)
      (VP (VBN:[1659..1663] been)
        (VP (VBN:[1664..1673] concluded)
          (NP-3 (-NONE-:[1673..1673] *))
          (SBAR-4 (IN:[1674..1678] that)
            (S
              (SBAR-ADV (WRB:[1679..1683] when)
                (S
                  (NP-SBJ-2
                    (NP (DT:[1684..1685] a)
                       (NN:[1686..1699] phenothiazine)
                       (NN:[1700..1711] neuroleptic))
                    (,:[1711..1712] ,)
                    (PP (JJ:[1713..1717] such) (IN:[1718..1720] as)
                      (NP (NN:[1721..1730] promazine))))
                  (,:[1730..1731] ,)
                  (VP (VBZ:[1732..1734] is)
                    (VP (VBN:[1736..1748] administered)
                      (NP-2 (-NONE-:[1748..1748] *))
                      (ADVP (RB:[1749..1756] jointly))
                      (PP (IN:[1757..1761] with)
                        (NP (NN:[1762..1775] carbamazepine)))))))
              (,:[1775..1776] ,)
              (NP-SBJ-1
                (NP (DT:[1777..1778] a) (JJ:[1779..1785] slight)
                    (NN:[1786..1794] increase))
                (PP (IN:[1795..1797] in)
                  (NP (DT:[1798..1801] the) (JJ:[1802..1813] neuroleptic)
                      (NN:[1815..1828] concentration))))
              (VP (MD:[1829..1832] may)
                (VP (VB:[1833..1835] be)
                  (VP (VBN:[1836..1844] expected)
                    (NP-1 (-NONE-:[1844..1844] *))
                    (PP (IN:[1845..1847] in)
                      (NP
                        (NP (DT:[1848..1849] a) (JJ:[1850..1855] short)
                            (NN:[1856..1860] time))
                        (PP (IN:[1861..1866] after)
                          (NP (NN:[1867..1881] administration)))))
                    (,:[1881..1882] ,)
                    (S-ADV
                      (NP-SBJ (-NONE-:[1882..1882] *))
                      (VP (VBN:[1883..1891] followed)
                        (PP (IN:[1892..1894] by)
                          (NP-LGS (PRP$:[1896..1899] its)
                                  (JJ:[1900..1911] significant)
                                  (NN:[1912..1920] decrease)))))))))))))
    (.:[1920..1921] .)))

;section 14 Span:1925..1969
;PMID: 9112700 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1925..1929] PMID) (::[1929..1930] :) (CD:[1931..1938] 9112700)
        (NN:[1939..1940] -LSB-) (NNP:[1940..1946] PubMed) (::[1947..1948] -)
        (NN:[1949..1956] indexed) (IN:[1957..1960] for)
        (NNP:[1961..1969] MEDLINE-RSB-)))
